收入增长重返双位数：2024 年公司实现营收288.7 亿元（同比+10.2%，下同），其中肿瘤领域收入107.3 亿（+22.0%），占比37.2%；肝病领域收入34.4 亿（-10.1%），占比11.9%；外科镇痛领域收入44.6 亿（+18.9%），占比15.4%；呼吸领域收入31.5 亿（+6.2%），占比10.9%；心脑血管领域收入21.7 亿（-21.0%），占比7.5%。公司创新管线...
Source Link收入增长重返双位数：2024 年公司实现营收288.7 亿元（同比+10.2%，下同），其中肿瘤领域收入107.3 亿（+22.0%），占比37.2%；肝病领域收入34.4 亿（-10.1%），占比11.9%；外科镇痛领域收入44.6 亿（+18.9%），占比15.4%；呼吸领域收入31.5 亿（+6.2%），占比10.9%；心脑血管领域收入21.7 亿（-21.0%），占比7.5%。公司创新管线...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.